Priority 8 from the Mesothelioma PSP
| UNCERTAINTY: In mesothelioma, is there a role for intrapleural immunostimulants (drugs designed to stimulate an anti-cancer immune response, such as corynebacterium parvum extract) in addition to any other treatment? (JLA PSP Priority 8) | |
|---|---|
| Overall ranking | 8 |
| JLA question ID | 0025/8 |
| Explanatory note | Not available for this PSP |
| Evidence | No systematic reviews identified. Ongoing study - A Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy. |
| Health Research Classification System category | Cancer |
| Extra information provided by this PSP | |
|---|---|
| Original uncertainty examples | Much more research into immunotherapy and cancer cell DNA is required ~ Can the immune system be stimulated to fight mesothelioma? |
| Comparison | None identified |
| Submitted by | Patient x 2 |
| Outcomes to be measured | Survival |
| PSP information | |
|---|---|
| PSP unique ID | 0025 |
| PSP name | Mesothelioma |
| Total number of uncertainties identified by this PSP. | 53 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
| Date of priority setting workshop | 16 December 2014 |